drugset / Trial / NCT02582996

Cefalium® Compared to Tylenol® in the Treatment of Migraine Attacks

NCT02582996

Phase 3 Suspended 336 enrolled Ache Laboratorios Farmaceuticos S.A.
RandomizedParallel-groupOpen-labelTreatment

Summary

National clinical trials, phase III, randomized, open, parallel, study of superiority, in which three hundred thirty-six (336) participants of both sexes, aged between 18 and 65 years will be randomly allocated to one of two treatment groups. The Group 01 will use Cefalium® and group 02 will use Tylenol®.

Timeline

Start
2020-04
Primary completion
2021-04
Completion
2021-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acetaminophen Small molecule
Subject Caffeine Small molecule
Subject Dihydroergotamine Small molecule
Subject Metoclopramide Small molecule

Indications